APAC SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Asia Pacific Sodium Glucose Cotransporter Market Share by Companies and the Market is Segmented by Drugs (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/forxiga (Dapagliflozin), And Suglat (Ipragliflozin)) and Geography (Japan, South Korea, China, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, And Rest of Asia-Pacific). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

APAC SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Industry Overview

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is highly consolidated, with major manufacturers, namely Eli Lilly, Sanofi, and Novo Nordisk, with a global and regional market presence. The joint ventures that occurred between players in the recent past helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT-2 class drug.

Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Janssen Pharmaceuticals

  4. AstraZeneca

  5. Bristol Myers Squibb

  6. *Disclaimer: Major Players sorted in no particular order
Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market Concentration

APAC SGLT2 Inhibitors Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?